期刊
JOURNAL OF LIPID RESEARCH
卷 58, 期 7, 页码 1267-1281出版社
ELSEVIER
DOI: 10.1194/jlr.R075796
关键词
low density lipoprotein receptor-related protein 1; gene expression; receptors/lipoprotein; transport
资金
- National Institutes of Health [P50AG016574, RF1AG051504, R01AG027924, R01AG035355, R01AG046205, P01NS074969]
- Cure Alzheimer's Fund
- Japan Heart Foundation
- Naito Foundation
- Mayo Clinic Alzheimer's Disease Research Center
- BrightFocus Foundation
- National Alzheimer's Coordinating Center (NACC) junior investigator award
Among the LDL receptor (LDLR) family members, the roles of LDLR-related protein (LRP) 1 in the pathogenesis of Alzheimer's disease (AD), especially late-onset AD, have been the most studied by genetic, neuropathological, and biomarker analyses (clinical studies) or cellular and animal model systems (preclinical studies) over the last 25 years. Although there are some conflicting reports, accumulating evidence from preclinical studies indicates that LRP1 not only regulates the metabolism of amyloid-beta peptides (A beta s) in the brain and periphery, but also maintains brain homeostasis, impairment of which likely contributes to AD development in A beta-independent manners. Several preclinical studies have also demonstrated an involvement of LRP1 in regulating the pathogenic role of apoE, whose gene is the strongest genetic risk factor for AD. Nonetheless, evidence from clinical studies is not sufficient to conclude how LRP1 contributes to AD development. Thus, despite very promising results from preclinical studies, the role of LRP1 in AD pathogenesis remains to be further clarified. In this review, we discuss the potential mechanisms underlying how LRP1 affects AD pathogenesis through A beta-dependent and -independent pathways by reviewing both clinical and preclinical studies. We also discuss potential therapeutic strategies for AD by targeting LRP1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据